Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

This study has been completed.
Sponsor:
Collaborators:
Rare Diseases Clinical Research Network
Information provided by (Responsible Party):
Peter Merkel, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00468208
First received: April 30, 2007
Last updated: January 30, 2014
Last verified: September 2013
  Purpose

Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study is to determine the safety and effectiveness of the medication abatacept in treating adults with mild relapsing WG.


Condition Intervention Phase
Wegener's Granulomatosis
Drug: Abatacept
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Safety of Abatacept - Number of Participants With Adverse Events [ Time Frame: Measured continuously from the screening visit through to the 6 month post-treatment study visit, up to 3 years and 4 months. ] [ Designated as safety issue: Yes ]

    This study examined the safety profile of this agent when used in Wegener's granulomatosis. Information was gathered on all adverse events with specific events being identified in the protocol for analysis that included the following:

    • Infection
    • Infusion reactions
    • Cytopenias
    • Transaminase elevation
    • Skin reactions
    • GI side effects
    • Malignancy

    All adverse events were reportable for this study.



Secondary Outcome Measures:
  • Disease Remission [ Time Frame: Measured monthly until common closing or early termination,up to 3 years and 4 months. ] [ Designated as safety issue: No ]

    Disease remission was measured by a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0.

    The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63.


  • Disease Improvement [ Time Frame: Measured monthly until common closing or early termination, up to 3 years and 4 months. ] [ Designated as safety issue: No ]

    Disease improvement was measured by a reduction in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG).

    The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63.


  • Meeting Common Closing [ Time Frame: Number assessed at the time of common closing, up to 3 years and 4 months. ] [ Designated as safety issue: No ]
    The number of subjects that reached the common closing date.

  • Disease Relapse [ Time Frame: Measured monthly until common closing or early termination, up to 3 years and 4 months. ] [ Designated as safety issue: No ]

    Disease relapse was measured by a rise in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of greater than or equal to 1 after achieving remission.

    The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63.



Enrollment: 20
Study Start Date: February 2008
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
Drug: Abatacept

A participant's abatacept dose depended on body weight and will remain the same throughout the study:

  • 500 mg of abatacept for body weight less than 60 kg
  • 750 mg of abatacept for body weight between 60 and 100 kg
  • 1000 mg of abatacept for body weight greater than 100 kg

Abatacept is administered in a 30-minute intravenous infusion.


Detailed Description:

Current standard treatment for WG involves various medications and is based on disease severity. Unfortunately, more than 50% of people experience a relapse after remission, placing them at risk for additional organ damage and medication toxicity. To prevent this, safer and more effective treatments for mild relapses are needed. Several studies have shown that activated T cells, a type of white blood cell important in regulating immune responses, play a role in WG. Abatacept, an immunoglobulin-based medication approved by the FDA to treat rheumatoid arthritis, acts by preventing T-cell activation and may be useful in treating mild relapses of WG. The purpose of this study is to determine the safety and effectiveness of abatacept in treating adults with mild relapsing WG.

Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter. A participant's abatacept dose is based on body weight and will remain the same throughout the study. Participants who are receiving maintenance immunosuppressive medications consisting of methotrexate, azathioprine, or mycophenolate mofetil at the time of enrollment will remain on these medications without dosage increase or reduction. Eligible participants may be on up to prednisone 15mg daily at the time of relapse. Following the development of relapse, participants may be treated with up to prednisone 30mg daily if necessary, but must to be back to the same dose that they had been on prior to relapse by Month 2. All study visits include medication review, physical exam, blood and urine collection, and questionnaires. A chest x-ray, computed tomography (CT) scan of the chest and sinuses, and lung function testing will occur at some study visits. Participants whose symptoms did not improved by Month 2 will be taken off abatacept. Any participants undergoing early termination or, after common closing, will undergo three follow-up study visits at 1, 3, and 6 months after the end of treatment.

  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of WG, meeting at least 2 of the 5 modified American College of Rheumatology (ACR) criteria. More information about this criterion can be found in the protocol.
  • Relapse of WG within the past 28 days where disease activity is confined to one or more of the following sites and where the symptoms/signs are of such a nature that the usual treatment would consist of the reinstitution or increase in GC to no more than prednisone 30mg daily and/or an increase or addition of a second immunosuppressive agent other than CYC (more specific information about this criterion can be found in the protocol):

    1. Sinonasal disease
    2. Oral mucosa ulceration
    3. Skin disease
    4. Musculoskeletal disease
    5. Pulmonary parenchymal disease
    6. Mild ocular disease
    7. Subglottic inflammation without significant stenosis
    8. Otic disease
    9. Breast involvement
    10. Urogenital involvement
    11. Other mild disease
  • Age of 15 years or older
  • Willing and able to undergo treatment and attend follow-up visits
  • Willing to use effective forms of contraception throughout the study

Exclusion Criteria:

  • Disease involvement that does not meet the criteria for mild disease. More information about this criterion can be found in the protocol.
  • Disease activity that would usually be treated first with cyclophosphamide
  • Presence of disease activity for which the investigator would normally treat the participant with more than prednisone 30 mg daily.
  • Receiving cyclophosphamide at study entry
  • Treatment with prednisone at a dose of more than 15 mg daily at the time of relapse. Subjects will be eligible if prednisone was initiated or dose increased in the period between relapse and study enrollment provided that the prednisone dose was 15 mg daily or less at the time when the relapse occurred, the prednisone dosage was increased no higher than 30 mg daily following the recognition of relapse, and that the dosage increase was made no more than 28 days prior to enrollment.
  • Active infection
  • HIV infected, hepatitis C virus infected, or positive for hepatitis B
  • Unable to follow through with study participation
  • Cytopenia, defined as platelet count less than 80,000/mm3, absolute neutrophil count less than 1500/mm3, OR hematocrit less than 20%
  • Kidney insufficiency
  • Use of illegal drugs
  • Any other uncontrolled disease that would prevent participation
  • History of cancer. More information about this criterion can be found in the protocol.
  • Received an investigational medication or procedure within 30 days of study entry
  • Received a live vaccine within 4 weeks of study entry
  • Positive tuberculin skin test. More information about this criterion can be found in the protocol.
  • Tuberculosis as indicated by radiographic evidence
  • Past treatment with rituximab within the past 12 months, or past treatment with rituximab more than 12 months ago where the B lymphocyte count has not returned to normal
  • Certain other diseases. More information about this criterion can be found in the protocol.
  • Pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00468208

Locations
United States, Maryland
The Johns Hopkins Vasculitis Center
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Boston University School of Medicine
Boston, Massachusetts, United States, 02118
United States, Minnesota
Mayo Clinic College of Medicine
Rochester, Minnesota, United States, 55905
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
University of Pennsylvania
Rare Diseases Clinical Research Network
Investigators
Principal Investigator: Carol A. Langford, MD, MHS The Cleveland Clinic
Principal Investigator: Peter A. Merkel, MD, MPH Boston University
  More Information

Additional Information:
Publications:
Responsible Party: Peter Merkel, Professor, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00468208     History of Changes
Other Study ID Numbers: RDCRN 5522, U54AR057319
Study First Received: April 30, 2007
Results First Received: September 20, 2013
Last Updated: January 30, 2014
Health Authority: United States: Federal Government

Keywords provided by University of Pennsylvania:
Vasculitis
Relapse
Wegener's
Treatment

Additional relevant MeSH terms:
Wegener Granulomatosis
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Systemic Vasculitis
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Autoimmune Diseases
Immune System Diseases
Abatacept
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 19, 2014